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Abstract 
Uncaria tomentosa is a medicinal plant native to Peru that has been traditionally used in 
the treatment of various disorders, including cancer. U. tomentosa is one of the best-selling herbs 
in the world and is used as an immunomodulatory, anti-inflammatory and anti-cancer remedy. 
This study assessed the effectiveness of U. tomentosa on the growth and survival of B16-BL6 
mouse melanoma cells. Both ethanol and PBS extracts of U. tomentosa extracts were tested in 
vitro and in vivo in order to evaluate their potential anticancer activity. In addition, different 
methods to measure the effect of treatment were used, including MTT assay, 
immunofluorescence (Ki67 protein and TUNEL assay) and the isogenic tumour transplantation 
model. The present results showed that U. tomentosa significantly inhibited cell proliferation and 
induced morphological changes in vitro. Furthermore, U. tomentosa was able to increase the 
percentage of apoptotic cells in a concentration-dependent manner. There was also decrease in 
the expression of Ki-67 (cell proliferation marker). Two experiments were performed to assess 
the ability of U. tomentosa to inhibit B16-BL6 cell growth in vivo. Mice were injected 
subcutaneously (on the top of the muscle) with B16-BL6 cells and tumours were allowed to 
progress for two weeks. In some animals, U. tomentosa extracts were injected intraperitoneal 
and intratumour. The animals were sacrificed and tumour diameters and weights were measured. 
The results showed that U. tomentosa caused a significant reduction in tumour weight but the 
tumor size was not significantly affected when compared to the controls. Interestingly, there 
were no significant differences in mouse weight for all treated groups. Overall, U. tomentosa 
showed promising results and caused a marked reduction in B16-BL6 melanoma cell growth.  
Keywords: Uncaria tomentosa, B16-BL6 mouse melanoma cells, anticancer. 
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1. Introduction  
1.1 Cancer  
Cancer is a very serious public health problem and one of the common major 
diseases worldwide. It covers a large group of diseases and oncology research is 
considered a great challenge (Parkin et al., 2005). Cancer involves over 200 diseases that 
affect all ages of humans and many of them are lethal (Alberts et al., 1994). Cancer cells 
grow in an abnormal manner because of changes in the genetic information of cells 
leading to formation of a tumour, which can affect any part of the body. All cases of 
cancer are thought begin as a single cell that has lost its ability to grow normally and to 
replicate with inappropriate control (Cooper, 2000). Tumors are divided into two types: 
malignant and benign. Malignant tumours are characterized by their rapid growth rate 
and their ability to invade neighboring tissues. Metastasis refers to the spread of the 
tumour cells to other parts of the body through the lymphatic system or the bloodstream. 
Benign tumours, are not cancerous. Benign tumors do not spread and invade neighboring 
tissues of the body. As well, they usually have a slower growth rate (Liotta, 1984; 
Folkman and Klagsbrun, 1987; Hanahan and Weinberg, 2011). Four basic features have 
been identified to aid in diagnosis of benign and malignant tumours: differentiation and 
anaplasia, growth rate, metastasis, and local invasion (Moscow and Cowan, 2011).  
Cancer is a major cause of death all around the world after cardiovascular 
diseases, and infectious disease and causes approximately 7.6 million deaths, which was 
13% of all deaths in 2008 (Xiaomei and Herbert, 2006; Ferlay et al., 2010). Patterns of 
cancer vary greatly from one region to another due to differences in lifestyle and 
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exposure to environmental agents (Parkin et al., 2002). Several factors could contribute 
to increasing the risk of cancer development, including age, genetics, and environmental 
factors  (Ames, 1998; Tzonou et al., 1996; Wild, 2008). Eighty percent of all cancer cases 
appear in individual’s aged 55 and older and result from deterioration in genome 
maintenance and low repair capacity (DePihno, 2000). Familial cancers are caused by 
inherited genetic mutation, and comprise approximately 5% of all cancer cases, but pose 
very high risk. Furthermore, environmental factors such as tobacco smoking, 
medications, radiation and some pro-carcinogenic foods have a significant involvement 
in cancer development with the high rate of deaths from lung cancer due to smoking as 
the biggest example (Hanahan and Weinberg, 2000). Understanding the causes of cancer 
is complex, since it can result from the interaction of many factors, particularly in old age 
(Smilenov, 2006). 
 
1.2 Skin Cancer  
Skin cancer is a prevalent type among men and women, especially in populations 
of Caucasian origin (Buettner and Raasch, 1998; Diepgen and Mahler, 2002). Skin is the 
largest organ in the body and has two main layers, the dermis, and the epidermis. Skin 
plays an important role in preventing various environmental problems, such as 
dehydration, sunburn and damage due to pollution (Rycroft et al., 2010). Statistics 
indicate that Australia has the highest rate of skin cancer, and constitutes about 80% of all 
malignant skin tumors while the lowest rates of skin malignancies have been reported for 
Black and Asian people (Jones, 1987; Rivers and Gallagher, 1995; Nggada et al., 2003). 
According to Canadian Cancer Society (2007), in Canada one third of all new cancer 
 3 
cases are skin cancers, and unfortunately the rate is on the rise. The increasing prevalence 
of skin cancer and its mortality rate could be due to stratospheric ozone depletion and 
atmospheric pollution (Williams and Kupper, 1996). Skin cancer has three main types, 
which are basal cell carcinoma, squamous cell carcinoma, and malignant melanoma 
(Leiter and Garbe, 2008). The majority of skin cancer cases are basal or squamous cell 
carcinomas while malignant melanoma cases are fewer (Weinstock, 1994).  
Basal and squamous cell carcinomas are extremely common and often do not 
cause death because they usually do not spread to other parts of the body. However, 
malignant melanoma is the most serious form and can be fatal, causing 90 percent of skin 
cancer deaths (Garbea et al., 2010). The Canadian Cancer Society reported 79,600 
patients diagnosed with skin cancer in Canada in 2011 (5,500 with melanoma and 74,100 
with non-melanoma skin cancer). It is suggested that melanoma cases will increase to 
9,070 cases in 2031 and non-melanoma skin cancer will be about 201,302 cases. In the 
United States, malignant melanoma was the cause of about 9,000 deaths in 2009 (Kushiro 
and Núñez, 2011).   
The main factor that contributes to the cause of skin cancer is exposure to 
ultraviolet (UV) rays from the sun or artificial sources, especially UVB with a 
wavelength of 290-320 nm (Williams and Kupper, 1996; Johnson, 2001). UVA and UVB 
play a critical role in shaping of melanoma. UVA can indirectly damage DNA through 
the generation of reactive oxygen species. UVB can directly damage DNA that leads to 
the apoptosis of keratinocytes or mutation in the sunburned cells (Situm et al., 2007). 
Melanoma has increased significantly among white populations since the 1950s 
(Mansson-Brahme et al., 2002; Ulmer et al., 2003; de Vries et al., 2004; Lasithiotakis et 
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al., 2006; Stang et al., 2006). It is considered the sixth most common cancer in men and 
the seventh in women all over the world. In 1997, 40,300 new melanoma cases were 
estimated, and approximately 7,300 patients died of the disease (Parker et al, 1997). In 
the United States classifies malignant melanoma as the sixth most common cancer, and 
approximately 44,200 new cases were reported in 1999 (Glocker-Reis et al., 1994; 
Landis et al., 1999). Linos et al. (2009) have shown the mortality of melanoma increasing 
annually at a rate of 0.4% from 1990 to 2004. In addition, increased annual mortality was 
1.7% for men and women over age 65, which were approximately 14.3 deaths per 
100,000 in 2004. It was noted that the mortality rate of men over 65 years was the 
highest.  
Malignant melanoma occurs in melanocytes that are mutated to have uncontrolled 
growth. Melanocytes are the cells that produce pigment in the epidermis. Melanoma can 
occur anywhere that melanocytes are located, such as the skin, mouth, gastrointestinal 
tract and eyes. Melanoma develops when unrepaired DNA damage in skin cells causes 
mutations that cause the cells to multiply rapidly and promotes the formation of 
malignant tumours. Melanoma tumour progression generally invade tumour limited to the 
epidermis followed by the radial growth phase, and the vertical growth phase (Kanavy 
and Gerstenblith, 2011).  
Melanoma has three general categories. The first and most common type of 
melanoma is called cutaneous melanoma (Mackie and Freudenberger, 1989). It occurs on 
the soles of feet and underneath the fingers and toenails. There are four types of 
cutaneous melanoma. Superficial spreading melanoma is considered the most common 
and can affect any site and all ages (Forman et al., 2008).  Nodular melanoma does not 
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show radial growth and can be pedunculated, nodular, or polypoid in form (Weinstock et 
al., 1988). Lentigo maligna melanoma can occur on sun-exposed skin, face and upper 
limbs of older patients (Forman et al., 2008). Acral lentiginous melanoma is common on 
plantar, palmar, and ungual skin (Lambert et al., 1985). The second category is mucosal 
melanoma, which is a rare form. It can infect the mucous membranes of the body, such as 
the nasal passages, the vagina, oral cavity, the anus, head and neck (Epstein et al., 1998). 
The third category is ocular melanoma also known as choroidal melanoma; which occurs 
in the eye (Gallagher et al., 1984).  
People with a large number of unusual moles, a family history of melanoma, light 
eye color, blond or red hair, fair skin, and freckles may have an increased risk of 
malignant melanoma (Bliss et al. 1995). There are many symptoms of melanomas 
including a spot or painful sore, a spot or lump that looks shiny, and a firm red lump 
especially these change in that shape, color and size. Melanoma can also appear as a new 
mole, and several signs have been determined to diagnose a mole as a cancer, such as 
asymmetry, a border that is irregular, uneven color, or a diameter that is increasing 
(Bishop et al., 2007).  
Melanoma treatments vary depending on the grade, size, location, and style of the 
melanoma and the patient's health (Neville et al., 2007). For advanced metastatic (Stage 
IV) melanoma, there is currently no effective treatment, but early diagnosis can improve 
patient survival, especially in the young (Parker et al., 1997). One treatment for 
melanoma can be a surgical wide excision, removing the melanoma and the normal skin 
around it. How much skin is taken will depend on the melanoma’s thickness (Veronesi 
and Cascinelli, 1991; Balch and Urist, 1993). Several other options for treatment have 
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also been recommended including freezing, scraping, radiotherapy and chemotherapy 
(Neville, 2007). Some targeted therapy and immunotherapy forms can be effective, such 
as interferon-α (IFN) or interleukin-2 treatment (Eggermont et al., 2008). Patients can 
receive doses of interferon-α (IFN) and interleukin-2 (IL-2) administered as adjunctive 
therapy in the second and third stages of melanoma (Creagan et al., 1986; Moschos et al., 
2006). Using chemotherapy alone is not effective in melanoma as compared to 
biochemotherapy, which is a combination of cytotoxic chemotherapy and 
immunotherapy. Ives et al. (2007) found that biochemotherapy can increase response 
rates, such as reducing some symptoms, but has negatives side effect of increased 
toxicity, as well as no improvement in survival.  
Various treatments for melanoma may lead to side effects including redness, 
dryness, rashes, itching, peeling and acne. Side effects of interferon (IFN) can cause 
chills, fever, fatigue, nausea and vomiting which can begin within 30-120 minutes after 
interferon treatment and can continue for many hours (Quesada et al., 1986). After a 
period of IFN treatment, patients often complain of memory loss, depression, cognitive 
slowing and sometimes-suicidal ideation (Trask et al., 2000). The majority of anticancer 
drugs are given intravenously, which can cause a dark area in the skin, especially for 
people who have dark skin. Side effects of chemotherapy depend on the type of drug dose 
and the length of treatment. These side effects can include hair loss and mouth sores, 
tiredness and vomiting (Griffin et al., 1996). According to the American Cancer Society, 
some chemo drugs can cause damaged nerve endings leading to symptoms, especially in 
the hands and feet, such as tingling sensations, sensitivity to cold or heat, or pain. 
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1.3 Medical Plants  
Treatment with plant-derived medicines could provide lower cost options and 
may have some benefits over treatment with chemicals and other procedures as well as 
fewer side effects (Corner et al, 2006; Vickers et al, 2006). Various studies in vitro and in 
vivo have proved the anti-inflammatory and anticancer effectiveness of treatment with 
extracts from many medicinal herbs (Aravindaram and Yang, 2010). For thousands of 
years several communities have relied on nature for all of their basic needs, including 
food, protection, transport, clothing and therapeutic uses. In the field of treatment, herbs 
have been chewed to relieve pain, or wrapped around a wound to relieve individuals from 
pain or discomfort. As well, plants have been the basis of advanced traditional medicine 
in places such as Egypt, India, Greece, and China dating to the beginning of history. 
These medical systems have been the basis of some modern drugs (Hong-Fang et al., 
2009). Sumerians and Akkaidians used medicinal plants in 2600 BC (Samuelson, 1999). 
In Egypt more than 700 drugs were recorded dating from 1500 BC. In China, over 600 
medicinal plants were reported in use around 1100 BC (Cragg et al., 1997).  
Compared to the beginning of time, when plants were the only form of 
medications for mankind, their use has now been relegated to a secondary role because 
advanced molecular biology and chemistry have permitted in the development of specific 
chemical compounds designed to target specific molecules. However, in recent years 
there has been a renewed interest in the use of natural products, which have played a 
major role in drug development (Hong-Fang et al., 2009). People in many countries care 
deeply about the use of alternative therapies and products, especially natural health 
products. For example, Canadians spent approximately C$ 2 billion on natural health 
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products in 1997 (Ghayur, 2010). Medicinal plants play a significant role in the fight 
against many diseases such as HIV/AIDS, Alzheimer's disease, malaria, improving lung 
function, and treating many infections (Balunas and Kinghorn, 2005; Singh et al., 2010). 
It has been suggested that herbal remedies can help to prevent or treat cancer by 
enhancing cellular defenses such as detoxifying and antioxidant enzyme systems as well 
as the induction of anti-inflammatory and antitumor activity (Aravindaram and Yang, 
2010).  
There are approximately 250,000 species of plants and at least a thousand of these 
species have been shown to have significant anticancer properties (Mukherjee et al., 
2001). According to the United States Food and Drug Administration, the analysis of new 
drugs confirmed for anticancer therapy during the period of 1981-2002 showed that 62% 
of these cancer drugs were of natural origin. These therapeutically used drugs were 
obtained through structural modification of natural compounds, or by creating new 
compounds, and are developed by modeling from a natural compound (Gordaliza, 2007).  
Krishnaiah et al. (2011) showed that several medicinal plants have significant 
antioxidant activity. Antioxidants decrease the oxidative stress in cells and are thus 
helpful in the treatment of many health problems such as cancer, cardiovascular diseases 
and inflammatory diseases. Studies show that there are significant antioxidant activities 
in extracts from the stems, roots, bark, leaves, fruits and seeds of several medicinal 
plants. Synthetic antioxidants, including butylated hydroxytoluene (BHT) and butylated 
hydroxylanisole (BHA) are presently utilized as food additives and a wide array of plant 
species have similar antioxidant potentials compared to these synthetics. These species 
include Diospyros abyssinica, Pistacia lentiscus, Geranium sanguineum L., 
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Sargentodoxa cuneata Rehd. Et Wils, Polyalthia cerasoides (Roxb.) Bedd, Crataeva 
nurvala Buch-Ham. Acacia auriculiformis A. Cunn, Teucrium polium L., 
Dracocephalum moldavica L., Urtica dioica L., Ficus microcarpa L. fil., Bidens pilosa 
Linn. Radiata, Leea indica, the Lamiaceae species, Uncaria tomentosa (Willd.) DC, 
Salvia officinalis L., Momordica Charantia L., Rheum ribes L., and Pelargonium 
endlicherianum. These natural antioxidants might be free of side effects and can be used 
as a substitute to synthetic antioxidants in the food industry and for preventive medicine 
uses (Krishnaiah et al., 2011). 
Ingredients extracted from plants played an essential role in the development of 
anticancer agents and have showed a relative lack of toxicity (Unnati et al., 2013). 
Anticancer agents may work through a variety of mechanisms, including direct impact on 
cancer cell growth, by restriction of blood supply to tumors, or through stimulating an 
immune response (Hynes and Lane, 2005; Sharma et al., 2011). Vinblastine, vincristine, 
irinotecan, topotecan, etoposide, podophyllotoxin, and paclitaxel are powerful anticancer 
agents that have been derived from plants (Cragg et al., 1997; Newman and Cragg, 
2007). Many medicinal plants have anticancer properties but most of these plants still 
have to be tested. 
Herbs contain many components, which work together to produce useful 
outcomes (D'Epiro, 1999). There are several factors that determine the effectiveness of an 
herb, such as geographical location, growth temperature, seasonal changes and the type 
of environment (climate, bugs and soil quality). Furthermore, when and how it was 
harvested and processed as well as whether the environment includes pollutants or not are 
also important (Avato et al., 2000; Sagdic, 2003). It has been found that natural 
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compounds are much more diverse and much more complex with regard to molecular 
structures compered to small molecular synthetic drugs and often have the ability to 
provide highly specific biological activities (Gonzales and Valerio, 2006).  
 
1.4 Uncaria tomentosa  
Uncaria is a genus of flowering plants. It has about 40 currently known species 
and most of the native species are distributed in tropical areas such as Asia, Africa, the 
Mediterranean and the neotropics (Mabberley, 2008). U. tomentosa is a large woody vine 
from the Rubiaceae family and Cinchonoideae subfamily, known as Cat’s Claw. It is 
widely used in the Amazon rainforest and throughout South and Central America (Rizzi 
et al., 1993; Reinhard, 1999). Its name comes from the hook-like thorns that resemble 
claws, which are commonly found in the jungle. The leaves have a smooth edge and 
grow in two opposite whorls (Keplinger et al., 1999). U. tomentosa has been traditionally 
used for medical therapies for decades. In Peru, many tribes such as the Aguaruna, 
Ashaninka, Cashibo, and Shipibo considered that U. tomentosa had a great number of 
uses and properties. In addition, they successfully used this species to treat various 
disorders (Keplinger et al., 1999).  
Cat's Claw may be useful in the treatment of several common diseases such as 
gastrointestinal disorders, diabetes, respiratory infections, several types of cancer, gastric 
ulcers, rheumatoid arthritis, hemorrhoids, herpes, multiple sclerosis and degenerative 
diseases (Heitzman et al., 2005). Currently, Cat's Claw is more popular and is considered 
one of the best-selling herbs in the United States. According to the American Cancer 
Society, U. tomentosa is often recommended for its positive impact on health and has 
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become one of the most popular herbs in the United States and Europe. However, allergic 
reactions can potentially affect people who are allergic to plants in the Rubiaceae family 
or different species of Uncaria. 
Since the 1970s, various studies have been conducted on U. tomentosa in Peru, 
Germany, Austria, England, Japan, Canada, the United States and other areas to learn 
more about the healing properties found in Cat's Claw extracts. Its components, including 
alkaloids, quinovic acid glycosides, polyhydroxylated triterpenes, flavonoids, catechins 
and sterols, can have great positive effects (De Matta et al. 1976; Aquino et al. 1989, 
1991; Muhammad et al. 2001; Kitajima et al. 2004; Heitzman et al. 2005). It has also 
been shown that Cat's Claw can kill viruses, bacteria and other microorganisms that cause 
disease. These components can protect healthy cells from becoming cancerous and inhibit 
the development and proliferation of tumours (Lamm et al., 2001; Åkesson et al., 2003).  
For two decades, researchers have examined many types and methods of 
extraction and monitored a large number of pharmacological properties of U. tomentosa 
including reduction of epithelial cell death in response to oxidant stress (Miller et al., 
2001), improvement in oedema through suppression of cyclooxygenase-1 and −2 
(Aguilar et al., 2002), cytoprotection by means of free radical scavenging, reduction of 
oxidative stress, and immediate suppression of TNF-α production (Sandoval et al., 2000; 
Allen-Hall et al., 2010). A large number of researchers have investigated the biological 
effects of U. tomentosa and the pentacyclic oxindole alkaloids that are present in this 
plant extract (Reinhard, 1999). Recently, laboratory experiments with many of these 
isolated alkaloids have demonstrated their antioxidant, immunomodulatory (Paniagua-
Pérez et al. 2009) and anti-neoplastic properties (Bacheret et al., 2005; García Prado et 
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al., 2007). However, other studies have proved that compounds different from the 
oxindole alkaloids such as triterpenes and quinovic acid glycosides can be partially 
responsible for the observed effects (Aquino et al., 1990, 1991). A third hypothesis 
indicates that the anti-inflammatory properties of U. tomentosa can be related to a 
synergy between a group of ingredients (Reinhard, 1999; Rizzi et al., 1993). Various 
extracts and compounds found in U. tomentosa can be useful as inhibitors of the growth 
and proliferation of tumours (Dreifuss et al., 2013).   
Additionally, Sheng et al. (2005) described the active components of a water-
soluble Cat's Claw extract, called C-Med-100, as preventing the proliferation of tumour 
cells and inflammatory responses by inhibiting cell growth and enhancing DNA repair. 
Quinic acid is a biologically active ingredient isolated from the bark of U. tomentosa that 
can be bioactive in vivo. Moreover, treatment with C-Med-100 can lengthen lymphocyte 
half-life and enlarge spleen cell numbers in mice given specific doses of this extract in 
their drinking water (Akesson et al. 2005). However, in other studies Cat’s Claw extracts 
and its components have caused antiproliferative activity in many cancer cells, including 
acute lymphoblastic leukaemia, MCF7 breast cancer, glioma, neuroblastoma and 
premyelocytic leukemia (Riva et al., 2001; Caballero et al., 2005; Bacher et al., 2006; 
Prado et al., 2007; Fazio et al., 2008; Rinner et al., 2009; García Giménez et al., 2010; 
Pilarski et al., 2010).  
U. tomentosa can be used as an antioxidant, has anti-apoptotic properties, and 
repairs cellular DNA damage (Sheng et al., 2001). Farias et al. (2011) have shown that U. 
tomentosa can be used as an adjunct treatment for patients also being treated with 
chemotherapy by promoting DNA repair and reducing the harmful effects of the 
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chemotherapy such as weight loss, nausea, secondary infections, and hair loss, as well as 
by increasing the number of myeloid progenitors. U. tomentosa was extremely effective 
as an adjuvant treatment for breast cancer and reduced the neutropenia resulting from 
chemotherapy. It was also able to promote DNA repair (Farias et al., 2012). This means 
the effects of U. tomentosa can be different on cell proliferation depending on the cell 
type involved. Dreifuss et al. (2013) compared the anti-neoplastic effects of a U. 
tomentosa brute hydroethanolic (BHE) extract with those of two different types of 
extracts. Walker-256 tumor cells injected into the pelvic limbs of male Wistar rats were 
used as a model. Results proved that the BHE extract and its BuOH fraction decreased 
tumour volume and weight, and modulated anti-oxidant systems. In addition, treatment 
increased the survival time for the animals that had tumours.  
Pilarski et al. (2010) studied the activity of U. tomentosa preparations on cancer 
cells by calculating the IC50 values for preparations with different quantitative and 
qualitative oxindole alkaloid composition. They found a strong relationship between the 
total oxindole alkaloid content (from 0.43% to 50.40% d.m.) and the antiproliferative 
activity of the preparations (IC50 from >1000 µg/ml to 23.57 µg/ml). As well, animal 
experiments on mice with Lewis lung carcinoma showed the presence of significant 
inhibition of tumour growth by B/W37--bark extracted in water at 37 °C, for 21 days at 
daily doses of 5 and 0.5 mg. Gurrola-Díaz et al. (2011) studied the inhibitory 
mechanisms of U. tomentosa extracts on the Wnt-signaling pathway, a main organizer of 
development and tissue homoeostasis. Results showed that pharmacological action of U. 
tomentosa contributes to inhibition of the Wnt-signaling pathway, downstream of beta-
Catenin activity.  
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Dreifuss et al. (2010) studied the antitumor and antioxidant effects of U. 
tomentosa hydroalcoholic extract on Walker-256 cancer cells. They found that U. 
tomentosa hydroalcoholic extract decreased tumour growth significantly and decreased 
the activity of AST. Treatment also increased CAT activity in the liver, while lowering it 
in the tumour tissue. In addition, SOD activity was reduced in the liver and in the tumour. 
Martino et al. (2006) examined the potential proapoptotic mechanism in three different 
tumoral cell lines using the activation of caspase3 in cells treated with root bark extracts 
of U. tomentosa. The results showed that treatment with a given extracts of U. tomentosa 
inhibited the cell growth of U. tomentosa aqueous extracts on SAOS (human ostesarcoma 
cell line), MCF7 (human breast carcinoma cell line) and HeLa cells (human cervical 
carcinoma cell line).  
Cheng et al. (2007) used four solvents with different polarities to isolate extracts 
from Cat’s Claw and then compared their relative effect on the proliferation of human 
premyelocytic leukemia, HL-60, cell lines. U. tomentosa n-hexane extracts (CC-H), ethyl 
acetate extracts (CC-EA) and n-butanol extracts (CC-B) had significantly higher effects 
on HL-60 cells compered to those extracted using methanol (CC-M) .The study found 
that the ability of treatment with CC-EA to induce apoptosis in HL-60 cells could be very 
important for medicine evolution. Rojas-Duran et al. (2012) suggested that mitraphylline 
was the main pentacyclic oxindolic alkaloids existing in the bark of the chloroformic 
extract of U. tomentosa. An In vivo murine model was examined and the effect of the U. 
tomentosa extract on the expression of inflammatory cytokines was examined. 
Mitraphylline inhibited approximately 50% of the release of interleukins 1α, 1β, 17, and 
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TNF-α, which are mediators of the immune response. Treatment also decreased 40% of 
the production of interleukin 4 (IL-4).  
Nuclear factor kappa B (NF-κB) is a transcription factor, which is made of 
subunits that include the p50, p65 p52, Rel B, and cRel subunits. It is an important link 
between cancer and chronic inflammation (Li et al., 2005). It has been shown that 
extracts of U. tomentosa inhibit NF-κB (Sandoval-Chacón et al., 1998; Akesson et al., 
2003). Caballero et al. (2005) have shown that intraperitoneal (i.p.) injection of an 
aqueous extract of U. tomentosa suppressed TNF-α and IL-6 secretion in response to 
lipopolysaccharide (LPS) challenge, as well as inhibit the growth of tumours and 
metastasis in mice. The in vitro and in vivo effects of a hydroethanolic extract of U. 
tomentosa on the viability of B16-BL6 tumour cells and on the inflammatory response, 
including secretion of TNF-α, IL-6 and nitric oxide [NO], was examined in C57BL/6 
mice. The results showed that U. tomentosa inhibited TNF-α, IL-6 and NF-κB activity in 
vitro. However, U. tomentosa did not demonstrate a significant cytotoxic effect in vitro at 
doses up to 300 µg/ml, but did prevent tumor growth and metastasis in vivo (Fazio et al., 
2008).  
Allen-Hall et al. (2007) showed that treatment of THP-1 monocyte-like cells with 
U. tomentosa extracts inhibited the MAP kinase signaling pathway and changed cytokine 
expression.  ELISA assays showed that treatment with U. tomentosa extracts increased 
LPS-dependent expression of IL-1beta by 2.4-fold, while inhibiting the LPS-dependent 
expression of TNF-alpha by 5.5-fold. They observed that treatment of LPS-stimulated 
THP-1 cells with U. tomentosa extracts prevented ERK1/2 and MEK1/2 phosphorylation 
in a dose-dependent manner. Allen-Hall et al. (2010) have shown that treatment of 
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monocyte-like THP-1 cells with U. tomentosa inhibits the production of the pro-
inflammatory cytokine TNF-alpha while increasing IL-1beta production. U. tomentosa 
inhibited the LPS-dependent activation of certain NF-kappaB and AP-1 subunits and 
improved cell death when NF-kappaB was inhibited.  
Continuing research has explored the immunoregulatory and antiviral activities of 
U. tomentosa in samples that were examined in an in vitro DENV contagion model. 
DENV-2 infected human monocytes were incubated with U. tomentosa hydro-alcoholic 
extracts or pentacyclic oxindole alkaloid-enriched or non-alkaloid fractions. The results 
showed the presence of inhibitory activity in both extracts and the alkaloidal fraction, 
decreasing DENV-Ag+ cell rates in treated monocytes. A microbead immunoassay was 
used for cytokine determination (TNF-alpha, IFN-alpha, IL-6 and IL-10) in infected 
monocyte culture supernatants. Decreased level of TNF-alpha and IFN-alpha were also 
observed and there was a tendency towards IL-10 modulation. The most effective 
treatment for decreasing monocyte infection rates and affective cytokine levels was with 
the alkaloidal fraction of U. tomentosa (Reis et al., 2008).  
Many researchers have studied the effects of medicinal plants on B16-BL6 cells, 
an aggressive murine melanoma (Hasegawa et al., 2002; Miyake et al., 2010). This cell 
line was derived from a melanoma from the skin of a C57BL/6 strain mouse that 
displayed fibroblast-like characteristics and that produced melanin. Cells could lose their 
ability to produce pigmentation in the long term.  
 
 
 
 17 
2. Objectives and Experimental Summary  
The present study examines the effects of U. tomentosa on B16-BL6 cells in vitro 
and in vivo in order to evaluate its potential anticancer activity. Three different methods 
were used including, which are the MTT Cell Proliferation Assay, immunohistochemistry 
and the male isogenic tumour transplantation model. The MTT Cell Proliferation Assay 
determines the cell proliferation rate in cells treated with U. tomentosa. 
Immunohistochemistry detects specific target antigens for example the Ki-67 protein and 
TUNEL assay. The Ki-67 protein is a cell proliferation nuclear that evaluates the growth 
fraction of a treated cell population. TUNEL is a method used to detect DNA 
fragmentation by labeling the terminal end of nucleic acids through terminal 
deoxynucleotidyl transferase (TdT). The isogenic tumour transplantation model is 
performed and tumour tissues are collected in order to measure the tumour diameters and 
weights of animals injected with B16-BL6 cells treated Uncaira extracts. Furthermore, 
the research determines whether U. tomentosa is an effective treatment for melanoma 
cancer that may eventually be appropriate for human patients in the future. 
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3. Materials and Methods  
3.1 Tissue Culture  
The B16-Bl6 cell line is an aggressive murine melanoma [American Type Culture 
Collection, Manassas, VA] that was maintained in tissue culture plates (Sarstedt, Laval, 
QC) in Dulbecco's modified Eagle's medium (DMEM, Hyclone, Logan, UT) 
supplemented with 10% fetal bovine serum (Hyclone) 100 µg/ml streptomycin, and 100 
U/ml penicillin (Invitrogen, Burlington, ON). Cells were incubated at 37°C in 5% CO2 
and subcultured 1:5 approximately every 3-4 days. For experiments, the cells were 
treated with media including Uncaria tomentosa extracts at various concentrations as 
specified. MTT assays and Immunofluorescence microscopy were performed in triplicate 
and the mouse experiments were performed and triplicate. 
 
3.2 Plant Extraction  
 The U. tomentosa powder was obtained from Rosario Rojas (Peru) or as a natural 
product supplement (from the lowland Peruvian Amazon Region, Iquitos. Cat’s Claw by 
now 500 mg, CODE 84618, Now Foods 60108) was extracted with PBS or 70% ethanol 
and the soluble fraction used in experiments. These extracts were shown to be very 
similar in cell growth studies and HPLC (not shown). For PBS extracts, 20 g of U. 
tomentosa powder was suspended in 180 ml water and 20 ml PBS and boiled for 1h. Bark 
debris was removed by centrifugation at 2000 x g for 10 min and the supernatant filtered 
through 0.22 µm filters. For the ethanolic extracts, 20 g of U. tomentosa powder was 
suspended in 200 ml 70% ethanol and boiled for 1h. The bark debris was removed by 
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centrifugation and the supernatant filtered through 0.22 µm filters. 
 
3.3 Cell Treatments  
The B16-BL6 cell line cultured in Dulbecco's modified Eagle's medium (DMEM), 
was treated with various concentrations of U. tomentosa extracts and incubated at 37°C 
in 5% CO2. The PBS extraction (1000 mg/ml) and the ethanolic extract (1000 mg/ml) 
were used as two different preparations of U. tomentosa. Before treatment, the two 
extract were suspended in DMEM media. For treatments, various doses of these stock 
solutions were used to treat the cell cultures. The two extract were utilized at the same 
dose as the solvent-only controls for each experiment. 
 
3.4 MTT Assay  
The B16-BL6 cells were plated on 96-well plates at a concentration of 2x103   
cells/ well and incubated overnight with 5% CO2 at 37°C. These cells were treated in 
media with 0, 4 µg/ml, 20 µg/ml, 40 µg/ml or 200 µg/ml of U. tomentosa extracted with 
70% ethanol or PBS on day 0. Cells were treated for four days in the continued presence 
of U. tomentosa without a media change. Furthermore, media was used as a negative 
control. On each day, cell viability was evaluated using the MTT assay. Each day, 10 
µl/ml of MTT solution was added to each well of a plate at a final concentration of 0.25 
mg/ml and incubated for 4 hrs. After the incubation, the media was removed and 100 
µl/well of dimethyl sulfoxide (DMSO) was added to dissolve the converted crystals. The 
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absorbance was read at 540 nm using a (Spectramax 340PC 389) plate reader. Analysis 
of the effect of treatment with different concentrations of U. tomentosa was performed by 
ANOVA using Graph Pad Prism Software. Each experiment was performed at least 3 
separate times.  
 
3.5 Cell Morphology  
The B16-BL6 cells were suspended in culture media in 24-well plates and 
incubated at 37°C for 4 hrs. Cells were treated with control, 4 µg/ml (low dose), 40 µg/ml 
(middle dose) and 200 µg/ml (high dose) of U. tomentosa extracted with ethanol or PBS. 
Cells were imaged daily for 4 days to determine the cell morphology between various 
treatments.  
 
3.6 Immunohistochemistry (Fluorescence) for ki-67 protein expression  
The B16-BL6 cells were plated on 6-well plates contains sterile glass coverslips 
in culture media and incubated at 37°C overnight. The B16-BL6 cells were treated with 
0, 4 µg/ml, 20 µg/ml, 40 µg/ml or 200 µg/ml of U. tomentosa extract and incubated at 
37°C for 72 hours. The treated cells were fixed with 4% formaldehyde (freshly prepared) 
for 5 minutes at room temperature, permeabilized by incubation in 0.1% Triton X-100 in 
PBS, and then blocked by incubation in 10% FBS, 0.5% BSA in PBS overnight at 4°C. 
The cells were stained with 100 µl primary anti-ki-67 antibody (titre 1:20) in block buffer 
for 60 minutes at room temperature. The primary antibody (solute) was removed and the 
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coverslips washed 3 times with PBS. The cells were then incubated with 100 µl goat anti-
mouse IgG, secondary antibody- FITC (green) (titre 1:100) in 100 µl block buffer for 60 
minutes at room temperature. Secondary antibody- FITC was removed and the coverslips 
were washed 3 times with PBS. Coverslips were then mounted on glass slides in 80% 
glycerol and analyzed under an LSM510 fluorescence microscope (Zeiss Canada). 
 
3.7 TUNEL assay  
B16-BL6 cells were grown on glass coverslips overnight at 37ºC. Cells were 
treated with U. tomentosa extract at concentrations of 4 µg/ml (low dose) or 200 µg/ml 
(high dose) for 72h.  The B16-BL6 cells were also treated with 6 µg/ml of camptothecin 
(high dose) as a positive control for apoptosis. Treated cells were fixed by incubation 
with 4% formaldehyde (freshly prepared) for 5 minutes at room temperature. Cells were 
permeabilized with 0.1% TritonX-100 in 0.1% sodium citrate (freshly prepared) for 2 
min on ice. Cells were washed twice with PBS and resuspended in 50 µl/well TUNEL 
reaction mixture (Roche).  Cells were incubated for 60 min at 37°C. Sample was washed 
twice in PBS and the cover slips were mounted on glass slides in 80% glycerol. An 
LSM510 fluorescence microscope was used for analysis. 
 
3.8 Animal Experiments  
A total of 50 syngeneic male C57BL/6 mice (8 weeks old) were used for these 
experiments (Charles River, Pointe-Claire, QB, Canada). Mice were received at 24-26 
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days of age and acclimatized in their cages for 3 weeks. All mice were placed in 
disposable plastic shoebox cages with 5 mice per cage using a high density, actively 
vented cage system (Innorack, Innovive Inc. San Diego, CA). The light: dark cycle was 
12:12 with the onset at 08:00 h local time. Temperature was maintained between 20°C 
and 21°C. The mice were fed on a standard pellet diet and water provided ad libitum. No 
other experiments were conducted on these animals except this current research. Two 
experiments were performed with twenty-five mice used for each experiment. Tumours 
were induced by injection of B16-BL6 cells, an aggressive murine melanoma in the right 
flank of C57BL/6 mice subcutaneously (on the top of the muscle). The mice were 
injected with 2 x 105 cells, suspended in 100 ul of PBS.  
All individual mice were injected with tumour cells and divided into 5 groups of 5 
animals each and randomly assigned as follows: Group 1; control had only B16-BL6 
tumours. Group 2; the mice were injected with 100 µl of 200 µg/ml ethanol extract of U. 
tomentosa intraperitoneal twice/week; Group 3; the mice were injected with 100 µl of 
200 µg/ml ethanol extract of U. tomentosa intratumour twice/week; Group 4; the mice 
were injected with 100 µl of 200 µg/ml PBS extract intraperitoneal twice/week; and, 
Group 5; the mice were with 100 µl of 200 µg/ml PBS extract intratumour twice/week. 
Tumour growth progressed for 10 to 14 days. The mice were weighed and their health 
monitored every two days during the experiment.  
In the first experiment, the intraperitoneal injection groups received the treatments 
for a period of 14 days (4 injections). The intratumour injection groups received the 
treatments for only week 2 (2 injections) after the appearance of palpable tumours. In the 
second experiment, all treatment groups (IP and IT) received the treatments for a period 
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of 14 days (4 injections). Following the treatment, the mice were euthanized for necropsy 
using CO2 exposure, in compliance with the CCAC recommendations. Tumours were 
collected and their diameter and weight were measured. The tumours were fixed in EFA 
(720 ml ethanol (100%), 180 ml distilled H2O, 50 ml glacial acetic acid and 50 ml 
formaldehyde) for future analysis.  
All processes were approved by the Laurentian University Animal Care 
Committee, protocol 2013-12-01, in accordance with guidelines established by the 
Canadian Council for Animal Care. Comparisons of mean values among different groups 
were performed using two-way analysis of variance (ANOVA) and post-hoc Tukey HSD 
tests (SPSS for windows). Differences were considered significant when p ≤ 0.05. 
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4. Results  
4.1 The effects of U. tomentosa on cell growth  
The effect of U. tomentosa on malignant cell growth was evaluated using the 
murine melanoma cell line, B16-BL6. There was significant inhibition in the B16-BL6 
cell growth in response to U. tomentosa treatment over a period of four days. During the 
experiment, it was found that the decrease in cell growth was a function of the U. 
tomentosa dose. An MTT Cell Proliferation Assay was used to determine the changes in 
cell viability in response to treatment with U. tomentosa extracted using two different 
solvents. These preparations are the ethanolic extract and PBS extract. During the in vitro 
experiment, the results showed that U. tomentosa extracted with 70% ethanol can 
significantly kill B16-BL6 cells more effectively than U. tomentosa extracted with PBS. 
In brief, the treatment of U. tomentosa with ethanolic extracts showed a significant effect 
at the lowest concentration added, and completely inhibited cell growth when the highest 
concentration was added (Figure 1). Treatment with U. tomentosa PBS extracts did not 
have a significant effect at the lowest concentrations but caused significant inhibition of 
cell growth at the higher concentrations (Figure 2). Overall, U. tomentosa extracted with 
ethanol or PBS were able to effectively kill B16-BL6 cells, especially at ≥ 200 µg/ml, 
which is the highest dose used. Finally, all experiments and data were run and analyzed 
with respect to triplicate independent experiments. 
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Figure 1: Effect of U. tomentosaon extracted with ethanol on the growth of the 
malignant B16-BL6 cell line 
U. tomentosa was added to B16-BL6 cells and growth measured using an MTT 
assay over a time of one-to-four days. The effect of U. tomentosa extracted with ethanol 
on the growth of the malignant B16-BL6 cell line at varying days compared to control 
(media) and ethanol suspended in DMEM media is shown. Cells were treated with low 
dose (4 µg/ml) Panel A, medium dose (40 µg/ml) Panel B, or high dose (200 µg/ml) 
Panel C U. tomentosa on day 0 and assessed for cell culture each day for 4 days. The data 
shows the results of a representative experiment from at least three independent 
experiments. 
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Figure 2: Effect of U. tomentosaon extracted with PBS on the growth of the 
malignant B16-BL6 cell line 
U. tomentosa was added to B16-BL6 cells and growth measured using an MTT assay 
over a time of one-to-four days. The effect of U. tomentosa extracted with PBS on the 
growth of the malignant B16-BL6 cell line at varying days compared to control (media) 
and PBS suspended in DMEM media is shown. Cells were treated with low dose (4 
µg/ml) Panel A, medium dose (40 µg/ml) Panel B, or high dose (200 µg/ml) Panel C U. 
tomentosa on day 0 and assessed for cell culture each day for 4 days. The data shows the 
results of a representative experiment from at least three independent experiments. 
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4.2 Cell morphology  
This experiment examined the morphology of the murine melanoma B16-BL6 
cell line in terms of shape, structure and appearance over a period of one-to-four days. 
Furthermore, the pictures of the B16-BL6 cells treated with U. tomentosa consistent with 
the cell growth data that was collected using the MTT Assay. In brief, treatment with U. 
tomentosa ethanolic extracts showed a significant atrophy of the cells at all 
concentrations added, and it completely atrophied the B16-BL6 cells when highest 
concentrations added (Figure 3). Furthermore, the treatment with U. tomentosa PBS 
extracts showed no observed atrophy at the lowest concentrations but significantly 
atrophied the cells when the doses were increased (Figure 4). Overall, increasing the dose 
of U. tomentosa extracts both (ethanol and PBS) caused evident atrophy in B16-BL6 cell 
and decreased the cells number, especially at day 3 and 4. 
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Figure 3: Effect of U. tomentosaon extracted with ethanol on the morphology of the 
malignant B16-BL6 cell line 
B16-BL6 cells were plated on 6-well plates tissue culture plated and grown in the 
presence of culture media (Panel A) 400x magnification, media supplemented with a low 
dose (4 µg/ml) (Panel B) 100x magnification, medium dose (40 µg/ml) (Panel C) 100x 
magnification or high dose (200 µg/ml) (Panel D) 400x magnification of U. tomentosa 
extracted in 70% ethanol. Images were taken using an Axiovert 100 microscope and 
Northern Eclipse Software. 
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Figure 4: Effect of U. tomentosaon extracted with PBS on the morphology of the 
malignant B16-BL6 cell line 
B16-BL6 cells were plated on 6-well plates tissue culture plated and grown in the 
presence of culture media (Panel A) 400x magnification, medium supplemented with a 
low dose (4 µg/ml) (Panel B) 100x magnification, medium dose (40 µg/ml) (Panel C) 
100x magnification or high dose (200 µg/ml) (Panel D) 400x magnification of U. 
tomentosa extracted in PBS. Images were taken using an Axiovert 100 microscope and 
Northern Eclipse Software. 
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4.3 Inhibition of B16-BL6 cell proliferation using Ki-67 protein 
expression  
The effects of U. tomentosa extracted with ethanol or PBS on the expression of 
the ki-67 proliferation nuclear in treated B16-BL6 cells were examined. The primary 
antibody was applied to identify the growth fraction of a treated cell population and 
detected with a FITC labeled secondary antibody. The fluorescence was visualized using 
an LSM510 fluorescence microscope (excitation at 488 nm and emission at 520 nm) with 
constant settings. In brief, there was a significant inhibition in the number of ki-67-
positive cells in cultures treated with the U. tomentosa extracts. Specifically, the cells 
stopped expression ki-67 especially at high doses of U. tomentosa extracted with ethanol 
(Figure 5). However, the treatment with U. tomentosa extracted with PBS showed a slight 
inhibition of ki-67 staining when compared to ethanol extracts. These results support our 
previous findings from the cell growth studies. 
 
 
 
 
 
 
 
 
 
 
 41 
Figure 5: Effect of U. tomentosaon extracted with ethanol on cell proliferation 
Various concentrations of U. tomentosa were added to treat the B16-BL6 cells over one-
to-three days. The cells were fixed and stained with an antibody against the cell 
proliferation nuclear ki-67 and a FITC labeled secondary antibody and images taken. The 
first panel shows the number of Ki-67-positive cells in cultures treated with the U. 
tomentosa extracted with ethanol represented by green fluorescence; The second panel 
shows the phase-contrast micrograph of the same field and the third panel shows the 
combination. Panel A: shows untreated cells. Panel B: shows a treated sample (low dose), 
Panel C: shows a treated sample (medium dose) and Panel D: shows a treated sample 
(high dose). 
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Figure 6: Effect of U. tomentosaon extracted with PBS on cell proliferation 
Various concentrations of U. tomentosa were added to treat the B16-BL6 cells over one-
to-three days. The cells were fixed and stained with an antibody against the cell 
proliferation nuclear ki-67 and a FITC labeled secondary antibody and images taken. The 
first panel shows the number of Ki-67-positive cells in cultures treated with the U. 
tomentosa extracted with PBS represented by green fluorescence; The second panel 
shows the phase-contrast micrograph of the same field and the third panel shows the 
combination. Panel A: shows untreated cells. Panel B: shows a treated sample (low dose), 
Panel C: shows a treated sample (medium dose) and Panel D: shows a treated sample 
(high dose). 
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4.4 Detection of apoptotic cells using TUNEL assay  
The TUNEL assay is used to detect DNA fragmentation, which is a hallmark of 
apoptosis, by labeling the terminal 3’-end of nucleic acids through terminal 
deoxynucleotidyl transferase (TdT). This method was used to confirm the previous 
results, which showed treatment with U. tomentosa extracts induced cell death. As the 
previous results indicated that U. tomentosa killed the B16-BL6 cells, the detection of 
apoptotic cells was confirmed using TUNEL assay and showed the presence of DNA 
fragmentation in the B16-BL6 cells following U. tomentosa treatment over a period of 72 
hours. As well, this method was applied for 24 hours using two different preparations 
ethanol (Figure 7) and PBS (Figure 8) to evaluate and compare the duration of treatment. 
In brief, the results showed that the apoptotic cells significantly increased as a result of 
treatment with the high doses of U. tomentosa extracted with ethanol (Figure 9). 
However, treatment with U. tomentosa extracted with PBS had a lower effect (Figure 10). 
Finally, the treatment of 72 hours showed more positive cells especially when treated at 
the highest dose.  
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Figure 7: Detection of DNA fragmentation in B16-BL6 cells treated with U. 
tomentosa using the TUNAL assay for 24 hours 
The effects of U. tomentosa extracted with ethanol on the B16-BL6 cells were evaluated 
using TUNEL assay to identify individual cells that were undergoing apoptosis. Various 
doses of U. tomentosa were added to treat the B16-BL6 cells for 24 hours. Cells were 
visualized and photographed using a fluorescence microscope: the green panel shows 
TUNEL stain, the second panel shows a phase-contrast micrograph of the cells, and the 
third panel shows the combination. At least five randomly chosen areas in every slide 
were used. Panel A: shows untreated cells. Panel B: shows a treated sample (low dose), 
and Panel C: shows a treated sample (high dose). 
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Figure 8: Detection of DNA fragmentation in B16-BL6 cells treated with U. 
tomentosa using the TUNAL assay for 24 hours 
The effects of U. tomentosa extracted with PBS on the B16-BL6 cells were evaluated 
using TUNEL assay to identify individual cells that were undergoing apoptosis. Various 
doses of U. tomentosa were added to treat the B16-BL6 cells for 24 hours. Cells were 
visualized and photographed using a fluorescence microscope: the green panel shows 
TUNEL stain, the second panel shows a phase-contrast micrograph of the cells, and the 
third panel shows the combination. At least five randomly chosen areas in every slide 
were used. Panel A: shows untreated cells. Panel B: shows a treated sample (low dose), 
and Panel C: shows a treated sample (high dose). 
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Figure 9: Detection of DNA fragmentation in B16-BL6 cells treated with U. 
tomentosa using the TUNAL assay for 72 hours 
The effects of U. tomentosa extracted with ethanol on the B16-BL6 cells were evaluated 
using TUNEL assay to identify individual cells that were undergoing apoptosis. Various 
doses of U. tomentosa were added to treat the B16-BL6 cells for 72 hours. Cells were 
visualized and photographed using a fluorescence microscope: the green panel shows 
TUNEL stain, the second panel shows a phase-contrast micrograph of the cells, and the 
third panel shows the combination. At least five randomly chosen areas in every slide 
were used. Panel A: B16-BL6 cells treated with 6 µg/ml camptothecin (high dose) were 
used as a positive control. Panel B: shows untreated cells. Panel C: shows a treated 
sample (low dose), and Panel D: shows a treated sample (high dose). 
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Figure 10: Detection of DNA fragmentation in B16-BL6 cells treated with U. 
tomentosa using the TUNAL assay for 72 hours 
The effects of U. tomentosa extracted with PBS on the B16-BL6 cells were evaluated 
using TUNEL assay to identify individual cells that were undergoing apoptosis. Various 
doses of U. tomentosa were added to treat the B16-BL6 cells for 72 hours. Cells were 
visualized and photographed using a fluorescence microscope: the green panel shows 
TUNEL stain, the second panel shows a phase-contrast micrograph of the cells, and the 
third panel shows the combination. At least five randomly chosen areas in every slide 
were used. Panel A: B16-BL6 cells treated with 6 µg/ml camptothecin (high dose) were 
used as a positive control. Panel B: shows untreated cells. Panel C: shows a treated 
sample (low dose), and Panel D: shows a treated sample (high dose). 
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4.5 Effect of U. tomentosa extracts on body weight, tumour weight and 
tumour size   
Two experiments were performed in vivo to determine the effect of U. tomentosa 
on the growth and survival of B16-BL6 mouse melanoma cells. Twenty-five male 
C57BL/6 mice were used for each experiment and divided into five groups. All 
individual mice were injected subcutaneously with 2 x 105 cells, an aggressive murine 
melanoma, into the hind limb the right flank. In the first experiment, the intraperitoneal 
injection groups received the biweekly treatments during 14 days (4 injections). The 
intratumour injection groups received the treatments only for week 2 (2 injections) 
(Tables 1-3). However, in the second experiment all treatment groups (IP and IT) 
received the biweekly treatments during 14 days (4 injections) (Tables 4-6).  
For statistical analysis, both experiments were combined using the two-way 
analyses of variance. The two-way analyses of variance indicated no significant 
differences between the five groups in terms of body weight (Table 7, Figure 11). In 
addition, two-way ANOVA showed no significant effects of experiment or group x 
experiment interaction on body weight. 
 However, animals treated with U. tomentosa had smaller tumours. Two-way 
ANOVA demonstrated significant effects of group (P < 0.001) on tumour weight (Table 
8, Figure 12). There was also a significant group x experiment interaction (P < 0.05).  
However, two-way ANOVA showed no significant effects of experiment on tumour 
weight. Further analysis with Tukey HSD tests showed significant differences between 
each of the four treated groups and the control (P < 0.05) but there were no significant 
differences between the four treated groups.  
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Furthermore, two-way ANOVA demonstrated significant effects of group (P < 
0.01) on tumour size (Table 9, Figure 13). However, two-way ANOVA showed no 
significant effects of experiment or group x experiment interaction on tumour size. 
Further analysis with Tukey HSD tests showed no significant differences between the 
four treated groups but there were significant differences between each of them and the 
control (P < 0.05).  
There was a significant relationship between tumour size and tumour weight (P < 
0.001). As the tumour weight was increased, the tumour size was increasing as well 
which indicated a direct proportional relationship (Table 10, Figure 14). The tumour size 
is significantly correlated to the tumour weight (r = 0.85, P < 0.001).  
Furthermore, two-way analyses of variance showed there were no significant 
main effects or interactions for the two levels of treatment (injection type: IP vs IT and 
extract type: ETOH vs PBS), which means that all four treatments reduced tumour weight 
in the same manner. 
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Table 1: Shows the values of mean mouse weight (g), standard deviation and 
standard error of different groups (N=4-5). 
Groups 
Weight 
N Mean Standard 
deviation 
Standard error of 
Mean 
Control 5 27.04 .79 .35 
ETOH IP 5 26.04 2.09 .93 
PBS IP 5 25.96 1.63 .73 
PBS IT 5 25.66 2.46 1.10 
ETOH IT 4 25.83 2.21 1.11 
 
 
Table 2: Shows the values of mean tumour weight (g), standard deviation and 
standard error of different groups (N=4-5). 
 
 
 
 
Groups 
Tumour weight 
N Mean Standard 
deviation 
Standard error of 
Mean 
Control 5 2.62 .98 .44 
ETOH IP 5 1.66 .29 .13 
PBS IP 5 .98 .51 .23 
PBS IT 5 1.50 1.02 .46 
ETOH IT 4 1.68 .62 .31 
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Table 3: Shows the values of mean tumour size (cm), standard deviation and 
standard error of different groups (N=4-5). 
Groups 
Tumour size 
N Mean Standard 
deviation 
Standard error of 
Mean 
Control 5 2.98 .77 .34 
ETOH IP 5 1.96 .57 .25 
PBS IP 5 1.74 .21 .09 
PBS IT 5 1.66 .64 .29 
ETOH IT 4 2.23 .29 .14 
 
 
Table 4: Shows the values of mean mouse weight (g), standard deviation and 
standard error of different groups (N=3-5). 
Groups 
Weight 
N Mean Standard deviation Standard error 
of Mean 
Control 5 26.94 2.51 1.12 
ETOH IP 5 24.48 1.94 .87 
PBS IP 4 26.68 2.45 1.22 
PBS IT 3 24.43 1.53 .88 
ETOH IT 4 22.73 1.11 .55 
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Table 5: Shows the values of mean tumour weight (g), standard deviation and 
standard error of different groups (N=3-5). 
Groups 
Tumour Weight 
N Mean Standard 
deviation 
Standard error of 
Mean 
Control 5 3.10 .22 .10 
ETOH IP 5 .72 .26 .12 
PBS IP 4 1.53 .96 .48 
PBS IT 3 2.13 .55 .32 
ETOH IT 4 .88 .32 .16 
 
 
Table 6: Shows the values of mean tumour size (cm), standard deviation and 
standard error of different groups (N=3-5). 
Groups 
Tumour size 
N Mean Standard 
deviation 
Standard error of 
Mean 
Control 5 2.74 .61 .27 
ETOH IP 5 1.54 .57 .26 
PBS IP 4 1.68 .71 .35 
PBS IT 3 2.17 .32 .19 
ETOH IT 4 1.50 .48 .24 
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Table 7: Shows the values of mean mouse weight (g), minimum, maximum, standard 
deviation and standard error of different groups (N=8-10). 
Group Count Mean Minimum Maximum Std. 
Deviation 
Standard Error 
of Mean 
Control 10 27.0 22.6 28.8 1.8 .6 
ETOH IP 10 25.3 22.9 28.6 2.1 .7 
PBS IP 9 26.3 24.0 29.1 1.9 .6 
PBS IT 8 25.2 22.7 29.5 2.1 .8 
ETOH IT 8 24.3 21.1 28.2 2.3 .8 
 
Table 8: Shows the values of mean tumour weight (g), minimum, maximum, 
standard deviation and standard error of different groups (N=8-10). 
Group  
(tweight) 
Count Mean Minimum Maximum Std. 
Deviation 
Standard Error of 
Mean 
Control  10 2.9 1.5 4.2 .7 .2 
ETOH IP 
 
10 1.2*** .3 2.0 .6 .2 
PBS IP 
 
9 1.2*** .3 2.5 .7 .2 
PBS IT 
 
8 1.7** .3 2.6 .9 .3 
ETOH IT 8 1.3*** .4 2.6 .6 .2 
 
Significantly different from the control (**P < 0.01 and ***P < 0.001). 
 60 
Table 9: Shows the values of mean tumour size (cm), minimum, maximum, standard 
deviation and standard error of different groups (N=8-10). 
Group 
(tsize) 
Count Mean Minimum Maximum Std. 
Deviation 
Standard Error 
of Mean 
Control  10 2.9 1.8 4.3 .7 .2 
ETOH IP 
 
10 1.8** .8 2.5 .6 .2 
PBS IP 
 
9 1.7** .8 2.3 .5 .2 
PBS IT 
 
8 1.9** .6 2.4 .6 .2 
ETOH IT 
 
8 1.9** .8 2.6 .5 .2 
 
Significantly different from the control (**P < 0.01). 
 
Table 10: Regression statistics for tumour size (cm) as a function of tumour weight 
(g) (N=45). 
 
 
Model R R Square Adjusted R 
square 
Std. Error of the 
Estimate 
1 .852a .726 .720 .375 
 
Model Summary 
a. Predictors: (Constant), tweight 
 61 
 
 
Model Sum of 
Squares 
df Mean Square F Sig 
1  Regression 16.060 1 16.060 114.177 P <.001a 
    Residual 6.048 43 .141   
    Total 22.108 44    
 
 
 
 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. Error Beta 
1            (Constant) .958 .115  8.366 P <.001 
 
Tweight .636 .060 .852 10.685 P <.001 
 
 
 
 
 
a. Predictors: (constant). tweight 
b. Dependent Variable: tsize 
ANOVAb 
Coefficientsa 
a. Dependent Variable: tsize 
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Figure 11: Effect of U. tomentosa extracts on body weight 
At necropsy, the tumours were fully removed from the mice and the tumour diameters; 
weights and body weights were measured. Animals were sacrificed 13 to 14 days post 
injection of cancer cells and this was dependent upon the level of distress exhibited by 
the animal. The figure shows the total body weight in grams for the five groups 
(+standard error, N= 8-10). No significant differences were found between these groups.  
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Figure 12: Effect of U. tomentosa extracts on tumour weight 
At necropsy, the tumours were fully removed from the mice and the tumour diameters; 
weights and body weights were measured. Animals were sacrificed 13 to 14 days post 
injection of cancer cells and this was dependent upon the level of distress exhibited by 
the animal. The figure shows tumour weight in grams for the five groups (+standard 
error, N= 8-10). Significant differences were found in the four treated groups compared 
to the control.  
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Figure 13: Effect of U. tomentosa extracts on tumour size 
 At necropsy, the tumours were fully removed from the mice and the tumour diameters; 
weights and body weights were measured. Animals were sacrificed 13 to 14 days post 
injection of cancer cells and this was dependent upon the level of distress exhibited by 
the animal. The figure shows the tumour size, the diameter in cm for the five groups 
(+standard error, N= 8-10). Significant differences were found in the four treated groups 
compared to the control.  
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Figure 14: The relationship between tumour size and tumour weight 
As the figure shows there is a direct positive proportional relationship between 
tumour size and tumour weight, which means increasing the tumour weight led to an 
increase in tumour diameter. Therefore, this support the idea that both tumour weight and 
tumour size indicate differences in U. tomentosa treated mice. 
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5. Discussion  
Uncaria tomentosa is a medicinal plant native to the Peruvian Amazon Basin. It 
has been used for decades in the treatment of various disorders and has been show to 
inhibit the growth and proliferation of tumours. Researchers have tried to discover anti-
cancer compounds that can kill cancer cells but that also lack toxicity to normal tissues. 
With this aim in mind, U. tomentosa is important because the bark and root of this 
species have been applied in traditional medicine and in adjuvant therapy to restore 
health (Dietrich et al., 2014).  In addition, its ingredients such as alkaloids, terpenes, 
quinovic acid glycosides, flavonoids and coumarins have powerful properties. The 
various effects of U. tomentosa preparations can be due to the several of bioactive 
chemical structures, which can be complementary and/or synergic in their actions (Wirth 
and Wagner, 1997). The pentacyclic oxindole alkaloids are considered biomarkers in 
alcoholic extracts of U. tomentosa. As well, they are immunostimulants and can inhibit 
many cancer cells. However, the tetracyclic oxindole alkaloids can cause many effects on 
the cardiovascular system and are involved in DNA protection. Uncaria polyphenols 
(flavonoids) have powerful antioxidant, anti-inflammatory and anti-tumour activities 
(Wirth and Wagner, 1997; Pilarski et al., 2006). 
The inhibitory effects of some aqueous U. tomentosa extracts on tumour cell 
growth can be mediated by the induction of apoptosis (Sheng et al., 2000; De Martino et 
al., 2006). Furthermore, U. tomentosa extracts are capable of decreasing the productions 
of proinflammatory cytokines TNF-α and IL-6 in response to immune system stimulate. 
In addition, they can inhibit nitric oxide production and NF-κB activity (Caballero et al., 
2005; Fazio et al., 2008; Dreifuss et al., 2010). Using an U. tomentosa hydroalcoholic 
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extract in vivo, Dreifuss et al. (2010) revealed that the anti-tumour activity is partially a 
consequence of the ability of U. tomentosa to restore redox and metabolism homeostasis 
via downregulation of the NF-κB transcription factor and superoxide dismutase (SOD) 
activities. Several substances appear to be effective in synergy with the oxindole 
alkaloids or even independently of them, in order to exert some degree of selectivity on 
its locale of action. Further studies are needed in order to assess the degree of 
participation of these substances, or others, in the mechanisms by which U. tomentosa 
exerts its anti-neoplastic effects (Dreifuss et al., 2013). 
 
5.1 Effect of U. tomentosa extracts on cancer cell lines  
The previous studies showed that U. tomentosa had positive effects when used as 
an adjuvant treatment for cancer patients. Sheng et al. (2001) determined the effect of C-
Med-100 supplement on a human volunteer study. They observed in vivo that U. 
tomentosa water extracts (C-Med-100) reduced the adverse effects of chemotherapy by 
promoting DNA repair, mitogenic response and leukocyte recovery. In their study, twelve 
healthy adults were randomly selected and distributed to 3 groups with age and gender 
matched. One group was treated daily with a 250 mg tablet containing an aqueous extract 
of U. tomentosa, C- Med-100, and another group with a 350 mg tablet, for 8 weeks. 
There was a great decrease in DNA damage and an increase in DNA repair in the 
supplement groups (250 and 350 mg/day) when compared with controls. The results also 
showed an increased tendency of by lymphocyte proliferation in response to treatment 
with the mitogen phytohemagglutinin in the treatment groups (Sheng et al., 2001). 
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U. tomentosa water extracts are free of oxindole alkaloids, and have a wide range 
of biological activity such as DNA repair and anti-inflammatory properties. In another 
study, skin cultures were treated with or without 5 mg/mL C-Med-100, irradiated with 0-
100 mJ/cm2 UVB, and microscopically analyzed for necrosis, and for the level of 
pyrimidine dimers using immunofluorescent TT-dimer antibody staining. The results 
showed that co-incubation with C-Med-100 decreased skin cell death from UV exposure 
and increased DNA repair (Mammone et al., 2006). 
Araújo et al. (2012) studied the effect of U. tomentosa on reducing the harmful 
effects of chemotherapy via a randomized clinical trial. Patients that have Invasive Ductal 
Carcinoma-Stage II, who underwent a treatment regimen known as FAC (Fluorouracil, 
Doxorubicin, Cyclophosphamide), were distributed into two groups; the U. tomentosa 
treated with chemotherapy plus 300  mg dry U. tomentosa extract per day. The group 
treated only with chemotherapy and used as the control. Blood samples were collected 
and immunological parameters, antioxidant enzymes, and oxidative stress and blood 
counts were tested. The results showed that U. tomentosa decreased the neutropenia 
resulting from chemotherapy. As well, U. tomentosa was able to repair cellular DNA 
damage and increase survival rates amongst cancer patients.   
Farias et al. (2012) examined the effect of U. tomentosa in decreasing the side 
effects of chemotherapy and improving the antioxidant status of colorectal cancer (CRC) 
patients. This study was performed on 43 patients who were undergoing 
adjuvant/palliative chemotherapy with 5-Fluorouracil/leucovorin + oxaliplatin 
(FOLFOX4). They were divided into two groups. The first group was treated with 
chemotherapy plus 300  mg U. tomentosa daily for 12 weeks. The other group received 
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only the FOLFOX4 chemotherapy and was used as a control. During the treatment, blood 
samples were collected before each of the 6 cycles of chemotherapy. Furthermore, 
hemograms, oxidative stress enzymes, antioxidants, immunologic parameters, and 
adverse processes were tested. They observed that using 300  mg U. tomentosa daily 
during 6 cycles of FOLFOX4 did not cause any changes in the most prevalent adverse 
events, which no toxic effects were found. Moreover, the comet assay was performed as a 
method for the detection of DNA damage, demonstrated no differences between groups. 
This suggests that the effects of U. tomentosa supplementation vary depend on cancer 
type or chemotherapy type. 
However, the present results showed that U. tomentosa extracts inhibited the 
proliferation of B16-BL6 cells. In addition, U. tomentosa caused DNA fragmentation and 
increased the percentage of programmed cell death (apoptosis), which means its effects 
can be different on cell proliferation depending on the cell type involved. Therefore, 
different U. tomentosa extracts were examined in vitro and in vivo in order to evaluate 
their activity, with promising results.    
 
5.2 Anti- proliferation activity of U. tomentosa extracts  
Here the study showed that ethanolic extracts had significantly higher inhibitory 
effect compared to PBS extracts in a concentration-dependent manner. Similarly, Bors et 
al. (2011) studied the effects of the ethanolic and aqueous extracts of U. tomentosa on 
human red blood cells as well as evaluating of the prophylactic effects of those extracts 
on hemolysis induction, hemoglobin oxidation, and changes in the level of reactive 
oxygen species (ROS), lipid peroxidation and catechol. The extracts of U. tomentosa 
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examined slowed that the extent of hemoglobin oxidation and lipid peroxidation were 
reduced compared to ROS and hemolysis, provoked by treatment with 2,4-DCP. It has 
been suggested that ethanol extracts have more ability to inhibit oxidative processes in 
human red blood cells.  
In the current study, MTT assay was used to measure the cell viability and 
proliferation rate in vitro. The MTT assay depends on the conversion of MTT into 
formazan crystals in living cells, which evaluates mitochondrial activity. For most of the 
cell populations the total mitochondrial activity is linked to the number of viable cells 
(van Meerloo et al., 2011). MTT assays were conducted on multiple days to measure 
proliferation. According to the present experiment, the B16-BL6 cells malignant showed 
a significant inhibition in the cell growth in response to U. tomentosa treatment over a 
period of four days. Furthermore, U. tomentosa extracted with ethanol completely 
inhibited B16-BL6 cells especially at 200 µg/ml, which is the highest dose. As the doses 
were increased, the reduction of the cells was increased. For PBS extracts, the treatment 
with 200 µg/ml, which is the highest dose, killed most of the B16-BL6 cells. However, 
the treatment with lower doses did not cause any significant reduction in cell growth 
unlike the ethanol extraction. Thus, the ethanol extract is more effective as an anti-cancer 
agent compared to the PBS extract.   
Chen et al. (2011) studied the anti-tumor effect of Cryptotanshinone, which is the 
major active component of Salvia miltiorrhiza, on two melanoma cell lines with 
low/high-metastatic capacity (B16/B16-BL6). Cells were treated with various 
concentrations of Cryptotanshinone (0, 1, 10 and 25 µM) and for different times (4, 8, 12, 
16, 20 and 24 h) in vitro and MTT was used to determine the cell growth. Similar results 
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were obtained in B16-BL6 cells, suggesting that the treatment with Cryptotanshinone had 
greatly inhibited cell proliferation (Chen et al., 2011). These findings support our 
hypothesis that natural products such as U. tomentosa inhibited the B16-BL6 cells in a 
period of four days. 
 
5.3 Anti- proliferation activity of U. tomentosa extract (ki-67 protein 
expression)  
The expression of the Ki-67 protein is correlated to the regulation of the cell cycle 
and cell proliferation. It is expressed in proliferating cells during all active stages of the 
cell cycle (G(1), S, G(2), and mitosis), but is absent from resting cells (G(0)). The 
expression of the ki-67 protein is considered one of the most promising biomarker for cell 
proliferation. This experiment was performed in vitro using the anti ki-67 primary 
antibody to assess the ability of U. tomentosa to inhibit B16-BL6 cell proliferation. As 
the results showed, U. tomentosa extracted with ethanol was greatly effective in 
inhibiting proliferation of B16-BL6 cells especially at high doses. At the low doses, the 
experiment showed that there was a slight decrease in the level of proliferation. For PBS 
extracts, the treatment with 200 µg/ml, which is the highest dose, reduced the cell 
proliferation. However, the treatment with low doses did not show any significant 
reduction in vitro.  
Similar results using different natural products were found. Khan et al. (2014) 
showed that the oral administration of naturally occurring chitosan-based nanoformulated 
green tea polyphenol EGCG significantly inhibits prostate cancer cell growth in a 
xenograft model. Tumor from athymic nude mice was stained using polyclonal primary 
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antibody. The study showed that there was 4.1- to 5.9-fold less expression of Ki-67 and 
5.5- to 6.8-fold less expression of PCNA in mice tissues that treated with Chit-
nanoEGCG than control group. The apparent increase in ki-67 and PCNA 
immunostaining-positive cells was taken as clear evidence of carcinogenicity. Cell 
proliferation activity in tissues of non-lesion areas was increased. This study showed that 
the tumors in mice given Chit-nanoEGCG had lower ki-67 and PCNA-positive index 
when compared with EGCG-treated and control groups (Khan et al., 2014). 
 
5.4 DNA fragmentation by U. tomentosa 
The TUNEL assay is considered one of the major methods for detecting apoptotic 
programmed cell death. Specifically, it is used to detect apoptotic cells that undergo 
extensive DNA degradation in the late phases of apoptosis by labeling the terminal end of 
nucleic acids. The experiment showed that the apoptotic cells greatly increased as a result 
of the treatment with high doses of U. tomentosa extracted with ethanol in vitro. In 
addition, apoptotic cells were increased in B16-BL6 cells treated with U. tomentosa 
extracted with PBS at the highest dose but still showed a lower effect. At the low doses, a 
low level of apoptotic cells was found in B16-BL6 cells treated with U. tomentosa 
extracted with ethanol. However, no significant apoptotic cells were found at the low 
doses for PBS extracts.  
Different results were obtained for B16 and B16-BL6 cells treated with 
Cryptotanshinone at different concentrations (0, 1, 10 and 25 µM) over a period of 24 
hours. Then, cells were tested for apoptosis via TUNEL assay in order to evaluate the 
effect of Cryptotanshinone on B16 and B16-BL6 melanoma cell apoptosis. Similar 
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results were found for these two cell lines. The percentage of apoptotic cells was 
increased under the influence of Cryptotanshinone, but the effect was small. At 25 µM, 
Cryptotanshinone caused apoptosis in about 4% of cells (Chen et al., 2011). 
 
5.5 U. tomentosa extract had significant effects on tumour weight and 
size  
 Tumours were induced by the subcutaneous (s.c.) injection of 2 x 105 B16/BL6 
cells in 100 µl PBS into the hind limb the right flank of C57BL/6 mice in vivo. Two 
experiments were performed with twenty-five mice used for each experiment and divided 
into five groups. The effect of U. tomentosa on tumour diameters and weights were 
measured. In addition, the same method was applied for both experiments. However, the 
number of injections was increased for IT groups in the second experiment. In terms of 
mouse weight, no significant differences were found between individual mice. There was 
a significant inhibition in tumour weight but the tumor size is not significantly affected. 
Furthermore, there are no significant main effects or interactions between the levels of 
treatment, including injection type and both extracts. This means that all treatment groups 
reduced tumor weight in the same manner. 
Similarly, Fazio et al. (2008) studied the effect of a hydroethanolic extract of U. 
tomentosa on many cancer cells in vitro including B16/BL6 (murine melanoma), K1735 
(amelanotic murine melanoma), HT29 (human colon carcinoma), A549 (human lung 
carcinoma), WEHI 164 (mouse fibrosarcoma), and LEC (mouse liver endothelial cell 
line) and on B16-BL6 cells in vivo. In the laboratory, the results showed that U. 
tomentosa inhibited the cell growth at high doses of 100 and 300 µg/ml. These cell lines 
 78 
(HT-29, K1735 and WEHI) as well as the three primary cell preparations (huPBMC, 
muSplen and muPM) were more response to the extract than the B16/BL6, A549 and 
LEC cells. In addition, the ethanolic extract of U. tomentosa reduced inflammation and 
B16-BL6 melanoma growth in female C57BL/6 mice injected intraperitoneal with U. 
tomentosa. Furthermore, in vitro U. tomentosa inhibited tumor necrosis factor alpha 
(TNF-α), interleukin-6 (IL-6) and nitric oxide (NO) production. As well, NF-κB activity 
was inhibited.  
Caballero et al. (2005) proved that an aqueous extract of U. tomentosa was not 
cytotoxic for many cells at concentrations up to 3 mg/ml. However, Fazio et al. (2008) 
showed that the hydroethanolic extract of U. tomentosa had more cytotoxic for some of 
the tumor cell lines and the primary cells, but not for the B16-BL6 melanoma cells. 
Allen-Hall et al. (2010) demonstrated that U. tomentosa is able to elicit a response 
through an NF-κB-dependent mechanism. More studies are required to describe the 
mechanism by which U. tomentosa can affect this pathway could offer a means to 
improve anti-TNF-α therapies. 
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6. Conclusion  
The present results showed that U. tomentosa significantly inhibited the growth of 
B16-BL6 cells and induce morphological changes particularly with ethanol extracts in 
vitro. Extracts from plant was also able to increase the percentage of apoptotic cells in a 
concentration-dependent manner. In addition, there was a significant inhibition of 
proliferation as detected by a decrease in the percentage of tumor cells that were positive 
for Ki67 expression. The in vivo results showed that U. tomentosa caused a significant 
reduction in tumour weight but the tumor size is not greatly affected when compared to 
the controls. Interestingly, there were no significant differences in mouse weight for all 
treated groups. Overall, U. tomentosa extracts can provide an effective treatment for 
melanoma cancer that could be suitable for human patients. Therefore, it appears 
appropriate to perform new experiments, testing various U. tomentosa extracts against 
different neoplastic scenarios, both in vitro and in vivo, and thus achieve a better 
understanding of the overall therapeutic potential of this plant. 
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